Reilly Kevin C sold $74K of KMTS

Reilly Kevin C sold 2,932 shares of KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) at $25.13 on 2026-09-08.

Original reporting
SEC EDGAR · Reilly Kevin C
Published Sep 11, 2026, 12:26 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 11, 2026, 12:54 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$KMTS
Neutral
high confidence
Mentioned
$KMTS
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$KMTSNeutralLow
01

Why it matters

The disclosed sale is modest and does not alter the company's valuation.

02

Market read

Minor insider sale with limited trading relevance.

03

What to watch

No additional corporate actions or news accompany the filing.

Relevance 3/10Novelty 5/10Timing: post-market 2026-09-08

Background

SEC Form 4 filing discloses insider transactions for public companies.

Company-level read

Ticker impact

$KMTSNeutralHigh confidence
Context

Director Kevin Reilly sold 2,932 shares for $73,677 on 2026-09-08, reducing his stake to 5,368 shares.

Expected impact

No significant impact expected.

Evidence & confidence

The sale size is small relative to market cap and does not signal a change in company fundamentals.

Market effects

None

None

None

Counterpoint

Insider sale could be routine and not indicative of future performance.

Key entities

  • KestrA Medical Technologies, Ltd.

    Medical device manufacturer listed on NASDAQ under KMTS.

  • Kevin Reilly

    Director of KestrA Medical Technologies.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$KMTSMedAI 8/10

Kestra study shows 100% shock conversion in wearable defibrillator

Kestra Medical Technologies (KMTS) reported 100% conversion success in its ASSURE Wearable Cardioverter Defibrillator study, meeting safety and effectiveness goals. The study, involving 21,612 patients, showed a 0.0065 inappropriate-shock rate and 94% of patients with no false alarms. The company plans an algorithm update to reduce inappropriate shocks by 70%.

$KMTSHigh

Why is Kestra Medical stock gaining today?

Kestra Medical Technologies (KMTS) stock rose 0.4% to $29.50 in pre-market trading after Evercore ISI initiated coverage with an Outperform rating and $34.00 price target. The firm cited Kestra's potential in the wearable cardioverter defibrillator market, projected 30%+ annual revenue growth, and gross margin expansion to mid-70% by 2030. The move contrasts with a mixed broader market.

$KMTSHighAI 8/10

Kestra Medical Technologies Signals Profitable Growth Path

Kestra Medical Technologies (KMTS) reported Q1 revenue of $31M, up 60% YoY, with gross margin at 56.5%, up from 45.7% YoY. The company raised 2027 revenue guidance to $141M and expects profitability within a few years. Management highlighted strong growth drivers, including market expansion and automation.